- Home
- CANF vs NCRA Comparison
CANF vs NCRA Comparison
Compare CANF & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | NCRA |
|---|---|---|
| Founded | 1994 | 2002 |
| Country | Israel | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.6M |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CANF | NCRA |
|---|---|---|
| Price | $3.45 | $0.25 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 938.6K | 543.8K |
| Earning Date | 03-26-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,627,944.00 |
| Revenue This Year | $2,715,455.50 | N/A |
| Revenue Next Year | $101.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.17 |
| 52 Week High | $10.40 | $2.40 |
Technical Indicators
Market Signals| Indicator | CANF | NCRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 51.70 |
| Support Level | $2.89 | $0.18 |
| Resistance Level | $4.74 | $0.32 |
| Average True Range (ATR) | 0.35 | 0.02 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 52.80 | 57.01 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.